Olanzapine Teva (Olanzapine)

Olanzapine works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain. This antagonism reduces excessive dopamine and serotonin activity, which are linked to psychotic symptoms and mood disturbances, thereby providing antipsychotic and mood‑stabilising effects.

The dosage of Olanzapine Teva is individually determined by a qualified prescriber based on the patient’s clinical condition, response to therapy, and tolerability. Physicians typically start with a low dose and may adjust it gradually to achieve optimal therapeutic benefit.

Safety data for Olanzapine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To order Olanzapine Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olanzapine is an atypical antipsychotic with strong affinity for both dopamine and serotonin receptors, offering effective control of psychotic symptoms and mood stabilization. Compared with agents such as risperidone or haloperidol, Olanzapine may have a higher risk of metabolic side effects but often provides better efficacy for certain mood symptoms.

Olanzapine tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date indicated on the label.

Olanzapine is taken orally as a tablet. It should be swallowed whole with water, and can be taken with or without food. Patients should follow the prescriber’s instructions regarding timing and whether the dose should be taken in the morning or evening.

The most serious risks include neuroleptic malignant syndrome, a potentially fatal reaction characterised by fever and muscle rigidity; tardive dyskinesia, which involves involuntary movements after long‑term use; and significant metabolic changes such as hyperglycaemia or new‑onset diabetes.

Olanzapine is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is advised for individuals with severe cardiovascular disease, uncontrolled diabetes, or a history of neuroleptic malignant syndrome. The medication should be avoided in patients where the risk outweighs the therapeutic benefit.